Loading...
01/10 19:48
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals mixed signals. Positives include potential $37 million milestone payment from OpRegen, new manufacturing processes, and strategic partnerships. However, the significant net loss, unclear management responses, and reliance on future funding present risks. The Q&A highlights potential expansion with the CIRM grant and partnership strategies, but uncertainties remain. Overall, the sentiment is balanced, leading to a neutral stock price prediction.
Revenue Total revenues were $3.7 million, a decrease of approximately $0.1 million as compared to $3.8 million for the same period in 2024. The decrease is primarily driven by lower royalty revenue and other service revenues recognized of $0.3 million, partially offset by more collaboration revenues of $0.2 million.
Operating Expenses Total operating expenses for the third quarter were $7.5 million, a decrease of $0.1 million as compared to $7.6 million for the same period in 2024.
R&D Expenses R&D expenses were $3.3 million, an increase of $0.1 million as compared to $3.2 million for the same period in 2024. The net increase was primarily driven by $0.2 million for our OPC1 program, $0.4 million for our preclinical programs and other undisclosed programs, partially offset by $0.5 million for our OpRegen program.
G&A Expenses G&A expenses were $4.2 million, a decrease of $0.2 million as compared to $4.4 million for the same period in 2024. This decrease is primarily attributable to stock-based compensation expenses and services provided by third parties.
Loss from Operations Loss from operations was $3.8 million, which was in line with the comparative prior period loss.
Other Income/Expenses Other income expenses reflected other expenses of $26 million compared to other income of $0.8 million for the same period in 2024. The change was largely attributable to the noncash quarterly fair value remeasurement of the warrant liabilities of $26.6 million compared -- primarily due to change in our share prices as compared to the prior year and $0.2 million for exchange rate fluctuations related to Lineage's international subsidiaries.
Net Loss The net loss was $29.8 million or $0.13 per share compared to a net loss of $3 million or $0.02 per share for the same period in 2024. The change was primarily driven by the aforementioned warrant liability.
OpRegen: Genentech has expanded the clinical sites for the Phase IIa GAlette study to 15 locations, a significant increase from the previous year. Positive clinical outcomes, including improvements in retinal structure and visual acuity, have been reported. Genentech is also evaluating next-generation delivery devices for the program.
ReSonance: Lineage entered a partnership with William Demant Invest A/S (WDI) to fund up to $12 million for preclinical development of ReSonance, a cell transplant program for hearing loss. The program demonstrated the company's ability to develop new cell-based products efficiently.
Islet Cell Initiative: Lineage is working on scaling production of islet cells for Type 1 Diabetes treatment. Early work suggests potential for significant production scale improvements, which could address commercial viability challenges.
Partnership with WDI: The collaboration with WDI provides funding and access to expertise in hearing healthcare, showcasing Lineage's ability to attract external funding for its programs.
OpRegen Commercial Potential: The program's advancements and Roche/Genentech's continued support highlight its potential in the market for dry AMD treatment.
Manufacturing Innovations: Lineage has developed a high-scale GMP banking system and is leveraging it to expand its pipeline efficiently.
Financial Management: The company reported a cash position of $40.5 million, extending its operational runway into Q2 2027. It is also pursuing non-dilutive funding sources like grants and milestone payments.
Pipeline Expansion: Lineage is focusing on expanding its cell therapy platform by developing new assets and leveraging its manufacturing capabilities.
Type 1 Diabetes Initiative: The company is exploring the feasibility of a cell therapy program for Type 1 Diabetes, with a decision expected next quarter.
Regulatory and Clinical Trial Risks: The company does not have full visibility into the GAlette study enrollment or findings, which introduces uncertainty about the outcomes and progress of the OpRegen program. Additionally, the ultimate decision to advance the program lies solely with partners Roche and Genentech, which could delay or halt progress.
Competitive Pressures: The company faces competition from other entities developing their own versions of RPE suspension, including a multinational pharmaceutical company, which could impact the commercial potential of OpRegen.
Manufacturing and Scalability Challenges: The production scale for islet cells, particularly for Type 1 Diabetes, remains a significant challenge. Current differentiation processes yield insufficient quantities of islet cells, which could hinder commercial viability.
Funding and Financial Risks: The company is reliant on external funding sources such as grants, partnerships, and milestone payments. Any delays or failures in securing these funds could impact operations and strategic initiatives.
Economic and Market Conditions: The company’s financial results are influenced by market conditions, including share price fluctuations, which have led to significant noncash quarterly fair value remeasurements of warrant liabilities.
Strategic Execution Risks: The company’s ability to manage a larger portfolio of cell therapy assets while maintaining focus and fiscal discipline is a potential risk. Expanding the pipeline without losing focus or requiring excessive capital investment is a challenge.
OpRegen Program: Genentech has expanded the number of clinical sites for the Phase IIa GAlette study, with 8 new sites opened in the past 6 months, totaling 15 locations. This acceleration is seen as a positive signal for the program's future. Genentech is also evaluating next-generation delivery devices for OpRegen, which could improve safety and provide a competitive advantage. The program may advance into a controlled clinical trial, with potential surgical optimizations.
ReSonance Program: Lineage entered a partnership with William Demant Invest A/S (WDI) to fund up to $12 million for preclinical development of ReSonance, a cell transplant program for hearing loss. This collaboration demonstrates the company's ability to develop new cell-based products efficiently.
Islet Cell Initiative: Lineage is working on overcoming production scale limitations for islet cell transplants for Type 1 Diabetes. Early work suggests potential for significant production scale improvements, with a feasibility decision expected next quarter. Success could accelerate partnership opportunities.
CIRM CLIN2 Grant: Lineage is a finalist for a CIRM CLIN2 grant, which could provide up to $7 million in funding for the OPC1 spinal cord injury study. A decision is expected by December 11, 2025.
Platform Expansion: Lineage is leveraging its manufacturing platform to expand its pipeline, focusing on scalable and efficient cell therapy development. The company is exploring new cell types and expects to disclose its next indication by the next quarterly call.
Financial Guidance: Lineage's cash position of $40.5 million is expected to support operations into Q2 2027. Additional funding sources include potential CIRM grants, milestone payments from Roche-Genentech, and warrant capital of approximately $37 million if OpRegen advances into a comparator trial.
Market Trends and Growth: The company anticipates a more favorable biotech market in 2026, improving the cost of capital and supporting platform expansion. Lineage expects momentum from the second half of 2025 to continue into 2026.
The selected topic was not discussed during the call.
The earnings call reveals mixed signals. Positives include potential $37 million milestone payment from OpRegen, new manufacturing processes, and strategic partnerships. However, the significant net loss, unclear management responses, and reliance on future funding present risks. The Q&A highlights potential expansion with the CIRM grant and partnership strategies, but uncertainties remain. Overall, the sentiment is balanced, leading to a neutral stock price prediction.
The earnings call reflects strong financial performance with significant revenue growth and improved net income. Despite some management hesitance on guidance specifics, the overall sentiment is positive due to increased sales force efforts, higher YCANTH adoption, and robust gross margins. The cash position is solid with upcoming milestone payments. These factors outweigh concerns about market expansion challenges and financial obligations. Given the company's small size, the stock is likely to react positively, potentially in the range of 2% to 8%.
The earnings call indicates increased losses, higher operating expenses, and lack of specific guidance on key projects, which are negative factors. The Q&A reveals management's reluctance to provide clear timelines or specifics, which may concern investors. Despite some positive developments in manufacturing and strategic partnerships, the overall sentiment is negative due to financial performance and uncertainties.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
